Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Admedus Limited is 'Strong Sell'. Macroaxis provides Admedus buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Admedus positions. The advice algorithm takes into account all of Admedus Limited available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Admedus buy-and-hold prospective. Check also Admedus Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.
For the selected time horizon Admedus Limited has a mean deviation of 20.33, semi deviation of 21.03, standard deviation of 53.28, variance of 2839.29, downside variance of 2536.53 and semi variance of 442.21We provide buy or sell advice to complement the prevailing expert consensus on Admedus Limited. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Admedus is not overpriced, please confirm all Admedus Limited fundamentals including its Debt to Equity, Total Asset and the relationship between Net Income and Earnings Per Share . As Admedus Limited appears to be a penny stock we also recommend to validate its Price to Book numbers.
Odds of Distress
Admedus Returns Distribution Density
|Mean Return||5.26||Value At Risk||40|
|Potential Upside||30.95||Standard Deviation||53.25|
|Alpha over DOW||=||3.07|
|Beta against DOW||=||11.43|
Admedus Volatility Alert
Admedus Limited is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Admedus implied risk. Admedus Limited is a penny stock. Although Admedus may be in fact a good investment, many penny stocks are subject to artificial stock hype. Make sure you completely understand upside potential and downside risk of investing in Admedus Limited. We encourage investors to look for the signals such us message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
|Better Than Average||Worse Than Average||Compare Admedus to competition|
Admedus Fundamental Vs Peers
|Return On Equity||(65.41)%||(15.17)%|
|Return On Asset||(35.80)%||(15.64)%|
|Price to Earning||(3.20)X||40.69X|
|Price to Book||2.41X||14.44X|
|Price to Sales||0.97X||17.81X|
|Cash and Equivalents||3.27M||3.89B|
|Cash per Share||0.01X||5.17X|
|Debt to Equity||40.60%||0.72%|
|Book Value Per Share||0.03X||13.64X|
|Cash Flow from Operations||(7.18M)||1.25B|
|Earnings Per Share||(0.041)X||2.30X|
|Number of Employees||12||10.67K|
|Admedus Limited appears to be very risky and stock price may revert if volatility continues|
|Admedus Limited has some characteristics of a very speculative penny stock|
|Admedus Limited has high likelihood to experience some financial distress in the next 2 years|
|The company reported revenue of 15.81M. Net Loss for the year was (10.75M) with profit before overhead, payroll, taxes, and interest of 10.29M.|
|ADMEDUS has accumulated about 3.27M in cash with (7.18M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.|
Check also Admedus Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.